一美国顾问评议小组1月17日投票以6比5建议反对使用Sanofi—Synthelabo的Avapro以阻止2型糖尿病伴高血压的患者发生肾损害。美国食品与药物管理局(FDA)的外围专家组认为,Sanofi的市场合作者Bristol-MyersSquibb所提供的两组实验不够充分。 Avapro,一般被称为伊贝沙坦(irbesartan),血管紧张素Ⅱ受体拮抗剂,是一种已经被FDA批准的抗高血压的 A U.S. advisory panel on January 17 voted 6 to 5 to recommend against using Avapro with Sanofi-Synthelabo to prevent kidney damage in patients with type 2 diabetes and high blood pressure. The US Food and Drug Administration (FDA) peripheral expert group concluded that two sets of experiments provided by Sanofi’s market partner Bristol-Myers Squibb were not sufficient. Avapro, commonly known as irbesartan, an angiotensin II receptor antagonist, is an FDA-approved antihypertensive